Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Perrin, Richard J ^a   Payton, Jacqueline E ^a   Malone, James P ^a   Gilmore, Petra ^a   Davis, Alan E ^a   Xiong, Chengjie ^a   Fagan, Anne M ^a   Townsend, R Reid ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KERATIN; METHIONINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FRACTIONATION; HUMAN; ION CURRENT; LIQUID CHROMATOGRAPHY; MULTI AFFINITY FRACTIONATION; PHYSICAL PARAMETERS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCORING SYSTEM; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; TECHNICAL VARIABILITY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBROSPINAL FLUID PROTEINS; CHROMATOGRAPHY, AFFINITY; HUMANS; MIDDLE AGED; PROTEOME; PROTEOMICS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84877905853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064314     Document Type: Article

References (62)

1. Holtzman DM, Morris JC, Goate AM, (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr1.
2. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. (2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68 (10):: 903-12.
3. Fagan A, Roe C, Xiong C, Mintun M, Morris J, et al. (2007) Cerebrospinal fluid tau/Aβ42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-49.
4. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, et al. (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69: 631-9.
5. Morris JC, Roe CM, Grant EA, Head D, Storandt M, et al. (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66: 1469-75.
6. Price J, Ko A, Wade M, Tsou S, McKeel D, et al. (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol 58: 1395-1402.
7. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, et al. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16: 4491-4500.
8. Perrin RJ, Fagan AM, Holtzman DM, (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
9. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
10. Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, et al. (2006) Inverse relation between in vivo amyloid imaging load and CSF Ab42 in humans. Ann Neurol 59: 512-519.
11. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65: 176-183.
12. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371-380.
13. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, et al. (2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50: 1464-1470.
14. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, et al. (2009) Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65: 927-934.
15. Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, et al. (2008) Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 70: 828-833.
16. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, et al. (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98: 10966-10971.
17. Chetelat G, Desgranges B, Sayette V, Viader F, Eustache F, et al. (2003) Mild cognitive impairment- Can FDG-PET predict who is to rapidly convert to Alzheimer's disease. Neurology 60: 1374-1377.
18. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, et al. (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6 (4):: e18850.
19. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM, (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78: 709-719.
20. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, et al. (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6: e16032.
21. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, et al. (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66: 48-54.
22. Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, et al. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13: 611-615.
23. Choe L, Dutt M, Relkin N, Lee K, (2002) Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23: 2247-2251.
24. Puchades M, Hansson S, Nilsson C, Andreasen N, Blennow K, et al. (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res 118: 140-146.
25. Hansson SF, Puchades M, Blennow K, Sjogren M, Davidsson P, (2004) Validation of a prefractionation method followed by two-dimensional electrophoresis- Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2: 7.
26. Castano E, Roher A, Esh C, Kokjohn T, Beach T, (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28: 155-163.
27. Finehout E, Franck Z, Choe L, Relkin N, Lee K, (2006) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61: 120-129.
28. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH, (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61: 120-129.
29. Hu Y, Malone J, Fagan A, Townsend R, Holtzman D, (2005) Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol & Cell Proteom 4: 2000-2009.
30. Hu Y, Hosseini A, Kauwe J, Gross J, Cairns N, et al. (2007) Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics- Clin Appl 1: 1373-1384.
31. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, et al. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3: 1486-1494.
32. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, et al. (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 95: 1461-1471.
33. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, et al. (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434-440.
34. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, et al. (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366-370.
35. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, et al. (2008) Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 8: 1576-1585.
36. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7: 125-133; discussion 173-180.
37. Dayon L, Hainard A, Licker V, Turck N, Kuhn K, et al. (2008) Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 80: 2921-2931.
38. Ogata Y, Charlesworth MC, Higgins L, Keegan BM, Vernino S, et al. (2007) Differential protein expression in male and female human lumbar cerebrospinal fluid using iTRAQ reagents after abundant protein depletion. Proteomics 7: 3726-3734.
39. Choe LDAM, Relkin NR, Pappin D, Ross P, Williamson B, et al. (2007) 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 7: 3651-3660.
40. Boja E, Hiltke T, Rivers R, Kinsinger C, Rahbar A, et al. (2011) Evolution of clinical proteomics and its role in medicine. J Proteome Res 10: 66-84.
41. Elliott MH, Smith DS, Parker CE, Borchers C, (2009) Current trends in quantitative proteomics. J Mass Spectrom 44: 1637-1660.
42. Tang K, Page JS, Smith RD, (2004) Charge competition and the linear dynamic range of detection in electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 15: 1416-1423.
43. Wang G, Wu WW, Zeng W, Chou CL, Shen RF, (2006) Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: Reproducibility, linearity, and application with complex proteomes. J Proteome Res 5: 1214-1223.
44. Deutsch EW, Lam H, Aebersold R, (2008) Data analysis and bioinformatics tools for tandem mass spectrometry in proteomics. Physiol Genomics 33: 18-25.
45. Zimmer JS, Monroe ME, Qian WJ, Smith RD, (2006) Advances in proteomics data analysis and display using an accurate mass and time tag approach. Mass Spectrom Rev 25: 450-482.
46. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
47. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood J, et al. (1995) Reduction of b-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648.
48. Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, et al. (2003) Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289: 2094-2103.
49. Storandt M, Grant E, Miller J, Morris J, (2006) Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67: 467-473.
50. Roche SL, O'Sullivan JJ, Kantor PF, (2010) Hypertension after pediatric cardiac transplantation: detection, etiology, implications and management. Pediatr Transplant 14: 159-168.
51. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383-5392.
52. Searle BC, (2010) Scaffold: A bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics 10: 1265-9.
53. Polpitiya AD, Qian WJ, Jaitly N, Petyuk VA, Adkins JN, et al. (2008) DAnTE: a statistical tool for quantitative analysis of-omics data. Bioinformatics 24: 1556-1558.
54. Karpievitch Y, Stanley J, Taverner T, Huang J, Adkins JN, et al. (2009) A statistical framework for protein quantitation in bottom-up MS-based proteomics. Bioinformatics 25: 2028-2034.
55. Neubert H, Bonnert TP, Rumpel K, Hunt BT, Henle ES, et al. (2008) Label-free detection of differential protein expression by LC/MALDI mass spectrometry. J Proteome Res 7: 2270-2279.
56. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, et al. (2010) Establishing the proteome of normal human cerebrospinal fluid. PLoS One 5: e10980.
57. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, et al. (2011) Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLoS One 6: e17287.
58. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, et al. (2010) Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 119: 669-678.
59. Abdi F, Quinn J, Jankovic J, McIntosh M, Leverenz J, et al. (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9: 293-348.
60. Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, et al. (2011) Identification of SPARC-like protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. J Alzheimers Dis 28 (3):: 625-36.
61. Fagan AM, Perrin RJ, (2012) Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers Med 6 (4):: 455-76.
62. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS, (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567.